X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (392) 392
hematology (211) 211
multiple myeloma (195) 195
oncology (190) 190
multiple myeloma - drug therapy (149) 149
multiple myeloma - pathology (131) 131
male (116) 116
animals (111) 111
female (105) 105
cancer (102) 102
cell line, tumor (98) 98
mice (98) 98
multiple myeloma - genetics (96) 96
bortezomib (89) 89
middle aged (83) 83
apoptosis (79) 79
multiple myeloma - metabolism (76) 76
aged (75) 75
abridged index medicus (64) 64
expression (63) 63
multiple myeloma - therapy (61) 61
adult (58) 58
apoptosis - drug effects (55) 55
tumor cells, cultured (54) 54
multiple myeloma - immunology (53) 53
mice, scid (51) 51
multiple-myeloma (48) 48
prognosis (47) 47
therapy (46) 46
antineoplastic agents - pharmacology (45) 45
survival (45) 45
activation (44) 44
dexamethasone (43) 43
lymphoid neoplasia (43) 43
treatment outcome (40) 40
cells (37) 37
thalidomide - analogs & derivatives (36) 36
antineoplastic combined chemotherapy protocols - therapeutic use (35) 35
genetic aspects (35) 35
thalidomide (35) 35
xenograft model antitumor assays (35) 35
antineoplastic agents - therapeutic use (34) 34
gene expression profiling (34) 34
lenalidomide (34) 34
gene expression (33) 33
mutation (33) 33
stem-cell transplantation (32) 32
cell biology (31) 31
growth (31) 31
health aspects (31) 31
human necessities (31) 31
hygiene (31) 31
immunotherapy (31) 31
medical or veterinary science (31) 31
preparations for medical, dental, or toilet purposes (31) 31
research (31) 31
bone-marrow (30) 30
care and treatment (30) 30
multiple myeloma - mortality (30) 30
aged, 80 and over (29) 29
bone marrow (29) 29
drug-resistance (29) 29
multidisciplinary sciences (29) 29
nf-kappa-b (29) 29
cell proliferation (28) 28
in-vitro (28) 28
boronic acids - pharmacology (27) 27
cell proliferation - drug effects (27) 27
hemic and lymphatic diseases (27) 27
monoclonal gammopathy (27) 27
myeloma (27) 27
pyrazines - pharmacology (27) 27
transplantation (27) 27
cytotoxicity (26) 26
dose-response relationship, drug (26) 26
gene expression regulation, neoplastic (26) 26
interleukin-6 (25) 25
peptides (25) 25
drug synergism (24) 24
life sciences (24) 24
proteins (24) 24
development and progression (23) 23
phosphorylation (23) 23
tumors (23) 23
analysis (22) 22
cell survival - drug effects (22) 22
chemistry (22) 22
metallurgy (22) 22
biochemistry & molecular biology (21) 21
chemotherapy (21) 21
induction (21) 21
inhibition (21) 21
interleukin-6 - pharmacology (21) 21
bone marrow - pathology (20) 20
dexamethasone - pharmacology (20) 20
disease progression (20) 20
gene-expression (20) 20
multiple myeloma - diagnosis (20) 20
multiple myeloma - enzymology (20) 20
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical cancer research, ISSN 1557-3265, 2017, Volume 23, Issue 15, pp. 4290 - 4300
Purpose: We study CD38 levels in immunosuppressive CD4(+)CD25(high)Foxp3(+) regulatory T cells (Treg) and further define immunomodulating effects of a... 
IN-VITRO | MICROENVIRONMENT | ONCOLOGY | IMMUNOTHERAPY | LENALIDOMIDE | DARATUMUMAB MONOTHERAPY | PERIPHERAL-BLOOD | PROLIFERATION | ANTITUMOR-ACTIVITY | CARCINOMA | CANCER | Leukocytes, Mononuclear - drug effects | Immunosuppression - methods | Cell Count | Humans | Interleukin-10 - blood | Multiple Myeloma - immunology | Immunologic Memory - drug effects | Transforming Growth Factor beta - blood | ADP-ribosyl Cyclase 1 - blood | T-Lymphocytes, Regulatory - immunology | Multiple Myeloma - drug therapy | Multiple Myeloma - pathology | T-Lymphocytes, Regulatory - drug effects | Antibodies, Monoclonal - administration & dosage | Immunosuppressive Agents - immunology | ADP-ribosyl Cyclase 1 - immunology | Cell Line, Tumor | Female | Gene Expression Regulation, Neoplastic - drug effects | Immunosuppressive Agents - administration & dosage | Immune Tolerance - drug effects | Multiple Myeloma - blood | Plasma | CD8 antigen | Multiple myeloma | Bone marrow transplantation | Recovery of function | Leukocytes (mononuclear) | Lymphocytes T | Immunosuppressive agents | Killer cells | Lymphocytes | CD38 antigen | Interleukin 1 | Bone marrow | Peripheral blood mononuclear cells | CD25 antigen | Foxp3 protein | Inhibition | Natural killer cells | Immunoregulation | Patients | CD4 antigen | Immunosuppression | Experimental design | Interleukin 10 | Lysis | Monoclonal antibodies | Health risk assessment | Cancer | IFNγ | CD107a | bone marrow stromal cells (BMSCs) | natural occurring Tregs (nTregs) | regulatory T (Treg) | CD38 | Isatuximab (Isa) (SAR650984) | PD1 | multiple myeloma (MM) | conventional T (Tcon) | tumor-induced Treg (iTregs)
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. e328 - e346
Journal Article
Cancer journal (Sudbury, Mass.), ISSN 1528-9117, 2019, Volume 25, Issue 1, pp. 1 - 1
Journal Article
Nature communications, ISSN 2041-1723, 2018, Volume 9, Issue 1, pp. 1 - 16
.... IpA isoforms are widely expressed in immune cells, differentially used during B-cell development or in different cellular environments, and can generate truncated proteins lacking C-terminal functional domains... 
MULTIPLE-MYELOMA | NONCODING RNA | CUL4A | EXPRESSION ANALYSIS | MULTIDISCIPLINARY SCIENCES | BINDING PROTEINS | ALTERNATIVE POLYADENYLATION | GENE-EXPRESSION | MESSENGER-RNA POLYADENYLATION | FACTOR-I | HUMAN BREAST-CANCER | Binding | Cell survival | Multiple myeloma | Ribonucleic acid--RNA | Human tissues | Proteins | Lymphocytes B | Polyadenylation | Isoforms | Plasma cells | Transmembrane domains | Deoxyribonucleic acid--DNA | Immune system
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 14, pp. 1311 - 1320
In this trial, 700 patients with myeloma were randomly assigned to receive RVD therapy (lenalidomide, bortezomib, and dexamethasone) with or without autologous... 
DIAGNOSED MULTIPLE-MYELOMA | MEDICINE, GENERAL & INTERNAL | PHASE-III | AUTOLOGOUS TRANSPLANTATION | DARATUMUMAB MONOTHERAPY | INITIAL TREATMENT | FOLLOW-UP | PREDNISONE PLUS THALIDOMIDE | RANDOMIZED CONTROLLED-TRIAL | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Stem Cell Transplantation | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Adult | Female | Maintenance Chemotherapy | Thalidomide - adverse effects | Dexamethasone - administration & dosage | Lenalidomide | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Bortezomib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bortezomib - adverse effects | Aged | Usage | Care and treatment | Bortezomib | Dexamethasone | Patient outcomes | Multiple myeloma | Transplantation of organs, tissues, etc | Dosage and administration | Autografts | Gastrointestinal tract diseases | Minimal residual disease | Stem cell transplantation | Peripheral neuropathy | Patients | Chemotherapy | Melphalan | Thromboembolism | Neutropenia | Life Sciences | Cancer
Journal Article
Nature communications, ISSN 2041-1723, 2014, Volume 5, Issue 1, p. 2997
Journal Article
Journal Article
by Alexandrov, Ludmil B and Nik-Zainal, Serena and Wedge, David C and Aparicio, Samuel A. J. R and Behjati, Sam and Biankin, Andrew V and Bignell, Graham R and Bolli, Niccolò and Borg, Ake and Børresen-Dale, Anne-Lise and Boyault, Sandrine and Burkhardt, Birgit and Butler, Adam P and Caldas, Carlos and Davies, Helen R and Desmedt, Christine and Eils, Roland and Eyfjörd, Jórunn Erla and Foekens, John A and Greaves, Mel and Hosoda, Fumie and Hutter, Barbara and Ilicic, Tomislav and Imbeaud, Sandrine and Imielinski, Marcin and Jäger, Natalie and Jones, David T. W and Jones, David and Knappskog, Stian and Kool, Marcel and Lakhani, Sunil R and López-Otín, Carlos and Martin, Sancha and Munshi, Nikhil C and Nakamura, Hiromi and Northcott, Paul A and Pajic, Marina and Papaemmanuil, Elli and Paradiso, Angelo and Pearson, John V and Puente, Xose S and Raine, Keiran and Ramakrishna, Manasa and Richardson, Andrea L and Richter, Julia and Rosenstiel, Philip and Schlesner, Matthias and Schumacher, Ton N and Span, Paul N and Teague, Jon W and Totoki, Yasushi and Tutt, Andrew N. J and Valdés-Mas, Rafael and van Buuren, Marit M and van ’t Veer, Laura and Vincent-Salomon, Anne and Waddell, Nicola and Yates, Lucy R and Zucman-Rossi, Jessica and Andrew Futreal, P and McDermott, Ultan and Lichter, Peter and Meyerson, Matthew and Grimmond, Sean M and Siebert, Reiner and Campo, Elías and Shibata, Tatsuhiro and Pfister, Stefan M and Campbell, Peter J and Stratton, Michael R and ICGC MMML-Seq Consortium and ICGC PedBrain and ICGC Breast Cancer Consortium and Australian Pancreatic Cancer Genome Initiative and ICGC Breast Canc Consortium and Australian Pancreatic Canc Genome
Nature (London), ISSN 1476-4687, 2013, Volume 500, Issue 7463, pp. 415 - 421
Journal Article
Blood, ISSN 1528-0020, 2015, Volume 125, Issue 20, pp. 3049 - 3058
Journal Article